ASH 2020 | SC daratumumab plus standard-of-care regimens in myeloma

Philippe Moreau, MD, Nantes University Hospital, Nantes, France, shares the findings of the Phase II PLEIADES study (NCT03412565) of subcutaneous (SC) daratumumab (DARA) administration in combination with standard of care treatments in multiple myeloma. Numerous sizeable Phase III trials in myeloma have demonstrated deep and durable responses to DARA IV when combined with lenalidomide-dexamethasone (Rd), bortezomib-melphalan-prednisone (VMP) and carfilzomib-dexamethasone (Kd). Subcutaneous delivery has the potential advantages of reduced infusion-related reactions and more rapid administration, so the PLEIADES trial investigated the safety and efficacy of these same standard of care regimens, with SC DARA in place of IV. Relapsed/refractory patients were enrolled to receive D-Kd and D-Rd, while newly diagnosed, transplant-ineligible patients were recruited for D-VMP treatment. To date, 66 patients have been treated in the D-Kd arm, achieving an overall response rate of 84.5%, comparable to that achieved in the CANDOR study with DARA IV. Primary analysis of the D-VMP and D-Rd arms have been reported prior, with extended follow up showing comparable clinical activity to DARA IV regimens. The occurrence of infusion-related reactions was low. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.